Business
Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its
About this update from Waldencast Plc
[{"type":"text","content":"Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices\nNEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Schweiger Dermatology as a key partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Schweiger will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs. “This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to introducing this innovative injectable, and we have the clinical depth and scale to evaluate how trial data translates into real-world outcomes across our diverse patient base,” said Dr. David Goldberg, Director of Cosmetic Dermatology and Clinical Research at Schweiger Dermatology. “Our providers see thousands of patients daily for both medical and cosmetic needs. That volume and expertise matter. This is exactly the kind of collaborative work that advances aesthetic dermatology. Obagi’s focus on integrated protocols and real-world insights aligns closely with how we prioritize accessible, high-quality patient care.” The ALOHA Program with Schweiger encompasses two complementary initiatives. A Phase 4 clinical study, led by Dr. David Goldberg at the Hackensack location, will evaluate Obagi® saypha® MagIQ™ through a structured research protocol with standardized data capture. In addition, a real-world evaluation program will give providers at select top-performing Schweiger aesthetic locations hands-on experience with the product and complete Obagi protocols, with the goal of driving patient satisfaction and strengthening provider-patient relationships. Initial program activities are expected to begin in early 2026. Schweiger will present initial findings at upcoming internal leadership meetings, highlighting the benefits of the new protocols and product within the Schweiger network. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing th...